Photo from wikipedia
CXCR4 mediates the retention and survival of acute myelogenous leukemia blasts in bone marrow and contributes to their resistance to chemotherapy. The authors evaluated a combination of the high‐affinity CXCR4… Click to show full abstract
CXCR4 mediates the retention and survival of acute myelogenous leukemia blasts in bone marrow and contributes to their resistance to chemotherapy. The authors evaluated a combination of the high‐affinity CXCR4 antagonist BL‐8040 with high‐dose cytarabine (HiDAC) chemotherapy in a phase 2a study of patients with relapsed and refractory AML.
Keywords:
relapsed refractory;
cxcr4 antagonist;
myelogenous leukemia;
phase study;
acute myelogenous
Journal Title: Cancer
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Cancer
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!